A group of major pharmaceutical companies raised the list prices of hundreds of prescription drugs in the years following Trump administration-era pricing agreements, according to a new Senate Democratic investigation.
The report reviewed pricing data and corporate filings and concluded that multiple manufacturers increased costs across a wide range of treatments despite public commitments to restrain drug price growth. As per NBC News, lawmakers said the findings challenge earlier assurances that voluntary deals would help stabilize or reduce drug costs for patients and government programs.
